Management of Olanzapine Transition and HCQ Initiation in SLE Patient with Psychosis

Rationale for Medication Change

Hydroxychloroquine (HCQ) is recommended for all patients with SLE as it reduces disease flares, prevents organ damage accrual, and improves long-term survival, according to the European League Against Rheumatism 1, 2

HCQ should be started at 5mg/kg/day based on real body weight, with a daily dose that can be divided into twice daily administration if gastrointestinal side effects occur, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) 1, 2, 3
Pre-treatment assessments should include measuring G6PD levels in men, especially those of African, Asian, or Middle Eastern origin, and baseline renal function, with a reduction in HCQ dose by 25% if eGFR <30 ml/min/1.73m², as suggested by the American College of Rheumatology 3, 4

Annual ophthalmologic examination should start after 5 years of therapy, or after 1 year if additional risk factors are present, as recommended by the American Academy of Ophthalmology 3, 4
Regular assessment of SLE disease activity should be performed, with the goal of achieving remission or low disease activity, according to the European League Against Rheumatism 1, 5

The treatment goal is to aim for remission or low disease activity in SLE, maintain psychiatric stability, and prevent SLE flares and organ damage with consistent HCQ therapy, as recommended by the European League Against Rheumatism 1, 2, 5

Monthly follow-up for the next 3 months should be performed to assess both psychiatric symptoms and SLE activity, with regular monitoring for potential side effects of both medications, as suggested by the American College of Rheumatology 1, 3, 4, 5